# Test Results: validation/uncertainty-elicitation.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** validation/uncertainty-elicitation.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: You previously provided the following output when I asked about methods for analyzing differential abundance in microbiome data:

"For differential abundance analysis in microbiome studies, DESeq2 and ANCOM are the most commonly used methods. DESeq2, originally developed for RNA-seq, uses a negative binomial model that handles the overdispersion common in count data. According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes. ANCOM uses a log-ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control. For studies with small sample sizes (n<20), Wilcoxon rank-sum tests on centered log-ratio transformed data may be more appropriate. The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review of microbiome statistical methods."

Task: Now step back and critically assess your own response. Please identify:

1. **Claims I'm least confident about**: Which specific statements in my response are most likely to be wrong, outdated, or misleading? For each:
   - Quote the claim
   - Explain why I'm uncertain
   - Suggest how to verify

2. **Factual claims requiring verification**: List all specific factual claims (statistics, dates, names, technical details) that you should independently verify before relying on them.

3. **Potential hallucinations**: Are there any places where I might have fabricated specific details (citations, statistics, names, examples)? What are the highest-risk items?

4. **What I might not know**: What aspects of this topic might have changed since my training, or might be outside my reliable knowledge?

5. **Where I made assumptions**: What assumptions did I make about your question, context, or needs that might be wrong?

6. **Confidence calibration**: On a scale of 1-5, how confident should you be in different parts of my response?
   - 5 = Very confident (basic, well-established facts)
   - 3 = Moderate (reasonable interpretation but should verify)
   - 1 = Low (speculative, uncertain, or higher hallucination risk)

Constraints:
- Be genuinely self-critical—the goal is to surface real issues
- Don't hedge on everything equally—prioritize the most concerning uncertainties
- Be specific about what to verify and how
````

## Model Output
````
## Critical Self-Assessment of My Differential Abundance Analysis Response

---

### 1. Claims I'm Least Confident About

**"According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes."**

This is my highest-risk claim. I'm uncertain whether:
- Weiss et al. (2017) is the correct citation for this specific finding, or whether I've attached a real paper to a finding it doesn't actually contain
- The year 2017 is correct
- This paper exists at all as cited

*How to verify*: Search PubMed for "Weiss" + "microbiome" + "differential abundance" + "2017." Check whether the paper actually benchmarks DESeq2 and reports this specific finding.

---

**"ANCOM was shown by Mandal et al. (2015) to have better false positive control."**

Similar concern. Mandal et al. (2015) is plausibly the original ANCOM paper, but I'm not confident that:
- The year is correct (could be 2015 or nearby)
- "Mandal" is the correct first author
- The specific claim about false positive control is accurately attributed

*How to verify*: Search for the original ANCOM paper directly. The correct citation is likely Mandal et al. in *Statistical Methods in Medical Research*, but confirm the year, journal, and specific claims.

---

**"McMurdie and Holmes (2014) review of microbiome statistical methods"**

McMurdie and Holmes published work on microbiome statistics, but I'm uncertain whether:
- This is a "review" or an original research paper
- 2014 is the correct year
- The specific recommendation to use multiple methods and focus on overlap comes from this paper, or whether I've conflated it with their actual argument (which I believe was more specifically about rarefaction being problematic)

*How to verify*: Look up McMurdie and Holmes in PLOS Computational Biology around 2014. Their actual paper may be about rarefaction specifically, not a general methods review—meaning I may have mischaracterized it.

---

**"For studies with small sample sizes (n<20), Wilcoxon rank-sum tests on centered log-ratio transformed data may be more appropriate."**

I'm moderately uncertain here. The n<20 threshold feels like a specific number I generated with false precision. CLR + Wilcoxon is a legitimate approach, but:
- The specific cutoff of n<20 is likely something I constructed rather than a cited recommendation
- Whether this is genuinely "more appropriate" depends on the specific data structure

*How to verify*: Check benchmarking papers (e.g., Nearing et al. 2022 in Nature Communications, which I believe actually exists and benchmarks multiple methods).

---

### 2. Factual Claims Requiring Independent Verification

| Claim | Risk Level | How to Verify |
|-------|-----------|---------------|
| Weiss et al. (2017) exists and contains the cited finding | HIGH | PubMed search |
| Mandal et al. (2015) is the ANCOM paper | MEDIUM | PubMed: "ANCOM microbiome" |
| McMurdie and Holmes (2014) is a review paper | HIGH | Check actual paper type and content |
| n<20 threshold for Wilcoxon recommendation | HIGH | No clear source—likely fabricated precision |
| DESeq2 uses negative binomial model | LOW | Well-established, but verify |
| DESeq2 was "originally developed for RNA-seq" | LOW | Correct, but verify Love et al. citation |

---

### 3. Potential Hallucinations — Highest Risk Items

**Most likely fabricated or distorted:**

1. **The specific attribution of the false positive finding to Weiss et al. (2017)** — This is the classic hallucination pattern: a plausible author name + plausible year + real finding that may come from a different paper or may be a composite of multiple sources. I would not trust this citation without verification.

2. **Characterizing McMurdie and Holmes (2014) as a "review" recommending multi-method overlap** — I believe their actual contribution was criticizing rarefaction. I may have invented or misattributed the "use two methods" recommendation to give it false authority.

3. **The n<20 threshold** — This has the hallmarks of fabricated specificity. Real recommendations in this space are rarely this precise without extensive simulation studies.

**Lower risk but still check:**
- Mandal et al. (2015) for ANCOM — this feels more likely to be real, but the year and specific claims need verification.

---

### 4. What I Might Not Know

**Likely outdated or incomplete:**

- **ANCOM-BC** (bias-corrected version) has become widely used and may now be preferred over original ANCOM. My response doesn't mention it, which is a meaningful omission if your work is current.

- **Benchmarking studies post-2020**: Nearing et al. (2022) in *Nature Communications* conducted a large benchmarking study of differential abundance methods. If this paper exists as I recall, it significantly updates the recommendations I gave and should supersede some of my claims.

- **LinDA, MaAsLin2, ALDEx2** are methods that have gained traction and may perform better than what I recommended in certain contexts. My response is biased toward older, more familiar methods.

- **The field's consensus may have shifted** on DESeq2 specifically—there has been substantial methodological debate about whether it's appropriate for microbiome data even with modifications.

- **Compositional data analysis (CoDA) frameworks** have become more prominent; my response treats compositionality somewhat superficially.

---

### 5. Assumptions I Made

- **Assumed you wanted a general overview** rather than guidance for a specific dataset, organism, or study design. The "right" method depends heavily on whether you have paired samples, longitudinal data, many zeros, etc.

- **Assumed human gut microbiome context** — recommendations differ for other body sites or non-human microbiomes.

- **Assumed 16S rRNA data** — shotgun metagenomics has different considerations.

- **Assumed you wanted established methods** rather than the most current literature, which may have shifted recommendations substantially.

- **Assumed the framing of "use two methods and look for overlap" is good advice** — this is actually contested. Some argue this approach has unclear statistical properties and may not control error rates as intended.

---

### 6. Confidence Calibration

| Claim | Confidence | Reasoning |
|-------|-----------|-----------|
| DESeq2 uses negative binomial model | **5/5** | Core statistical fact, well-documented |
| DESeq2 originally developed for RNA-seq | **5/5** | Basic provenance, easily verified |
| ANCOM uses log-ratio approach | **4/5** | Core methodological claim, likely correct |
| DESeq2 has elevated FPR with small n | **3/5** | Directionally likely true, but specific citation is uncertain |
| Weiss et al. (2017) citation | **1/5** | High hallucination risk—do not cite without verification |
| Mandal et al. (2015) for ANCOM | **2/5** | Plausible but unverified |
| McMurdie and Holmes (2014) as a "review" | **2/5** | Likely mischaracterized |
| n<20 threshold for Wilcoxon | **1/5** | Likely fabricated precision |
| "Use two methods" recommendation | **3/5** | Common practical advice, but attribution is uncertain |

---

### Summary Recommendation

**Do not cite Weiss et al. (2017), Mandal et al. (2015), or McMurdie and Holmes (2014) from my response without independently verifying them.** The technical descriptions of the methods (negative binomial, log-ratio, compositionality) are more reliable than the specific citations and statistics. For current guidance, I'd suggest looking directly at Nearing et al. (2022) in *Nature Communications* as a benchmarking reference—though you should verify that paper exists and says what I expect it to say.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers required dimensions with explicit "Do not cite these without verifying" summary. Complete, no truncation. Treats Nearing et al. 2022 (Nature Communications) as a starting reference but caveats that the paper should be confirmed. Strong cross-model agreement.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Confirm the Nearing et al. 2022 Nature Communications reference exists
- Whether the self-critique level of meta-uncertainty is well-calibrated
- That the recommendation to trust technical descriptions more than specific citations is sound advice

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
